Article
KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cells
1 Jan 2020
Abstract excerpt
Paclitaxel (PTX), a tubulin-binding agent, is widely used and has shown good efficacy in the initial period of treatment for non-small cell lung cancer (NSCLC). However, the relatively rapid acquisition of resistance to PTX treatments that is observed in virtually all cases significantly limits its utility and remains a substantial challenge to the clinical management of NSCLC. The aim of this study was to...
Topics
Join the communities discussing this publication.